Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells by Jagust, P. et al.
WJSC https://www.wjgnet.com 1410 November 26, 2020 Volume 12 Issue 11
World Journal of 
Stem CellsW J S C
Submit a Manuscript: https://www.f6publishing.com World J Stem Cells 2020 November 26; 12(11): 1410-1428
DOI: 10.4252/wjsc.v12.i11.1410 ISSN 1948-0210 (online)
ORIGINAL ARTICLE
Basic Study
Glutathione metabolism is essential for self-renewal and 
chemoresistance of pancreatic cancer stem cells
Petra Jagust, Sonia Alcalá, Bruno Sainz Jr, Christopher Heeschen, Patricia Sancho
ORCID number: Petra Jagust 0000-
0001-5291-251X; Sonia Alcalá 0000-





Author contributions: Jagust P and 
Sancho P performed the 
experiments, acquired and 
analyzed data; Alcalá S and Sainz 
Jr B compiled and validated the 
samples for RNAseq analysis; 
Heeschen C and Sancho P 
interpreted data, designed the 
study and wrote the manuscript; 
all authors approved the final 
version of the manuscript.
Supported by ERC Advanced 
Investigator Grant, No. Pa-CSC 
233460; European Community's 
Seventh Framework Programme, 
No. 602783; Instituto de Salud 
Carlos III and European Funds 
(FSE: “el FSE invierte en tu futuro” 
and FEDER: “una manera de hacer 
Europa”) Miguel Servet 
Fellowship, No. CP16/00121; and 
Fondo Investigaciones Sanitarias, 
No. PI17/00082.
Institutional review board 
statement: The study was 
reviewed and approved by the IIS 
Aragon Institutional Review 
Board.
Petra Jagust, Molecular Pathology Programme, Spanish National Cancer Research Centre 
(CNIO), Madrid 28029, Spain
Sonia Alcalá, Bruno Sainz Jr, Department of Biochemistry, Autónoma University of Madrid, 
Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC-UAM, Madrid 28029, Spain
Christopher Heeschen, Center for Single-Cell Omics & Key Laboratory of Oncogenes and 
Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, 
Shanghai 200025, China
Patricia Sancho, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza 50009, Spain
Corresponding author: Patricia Sancho, PhD, Senior Scientist, Hospital Universitario Miguel 
Servet, IIS Aragon, Isabel la Católica 1-3, Zaragoza 50009, Spain. psancho@iisaragon.es
Abstract
BACKGROUND 
Cellular metabolism regulates stemness in health and disease.  A reduced redox 
state is essential for self-renewal of normal and cancer stem cells (CSCs). 
However, while stem cells rely on glycolysis, different CSCs, including pancreatic 
CSCs, favor mitochondrial metabolism as their dominant energy-producing 
pathway. This suggests that powerful antioxidant networks must be in place to 
detoxify mitochondrial reactive oxygen species (ROS) and maintain stemness in 
oxidative CSCs. Since glutathione metabolism is critical for normal stem cell 
function and CSCs from breast, liver and gastric cancer show increased 
glutathione content, we hypothesized that pancreatic CSCs also rely on this 
pathway for ROS detoxification.
AIM 
To investigate the role of glutathione metabolism in pancreatic CSCs.
METHODS 
Primary pancreatic cancer cells of patient-derived xenografts (PDXs) were 
cultured in adherent or CSC-enriching sphere conditions to determine the role of 
glutathione metabolism in stemness. Real-time polymerase chain reaction (PCR) 
was used to validate RNAseq results involving glutathione metabolism genes in 
adherent vs spheres, as well as the expression of pluripotency-related genes 
following treatment. Public TCGA and GTEx RNAseq data from pancreatic cancer 
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vs normal tissue samples were analyzed using the webserver GEPIA2. The 
glutathione-sensitive fluorescent probe monochlorobimane was used to determine 
glutathione content by fluorimetry or flow cytometry. Pharmacological inhibitors 
of glutathione synthesis and recycling [buthionine-sulfoximine (BSO) and 6-
Aminonicotinamide (6-AN), respectively] were used to investigate the impact of 
glutathione depletion on CSC-enriched cultures. Staining with propidium iodide 
(cell cycle), Annexin-V (apoptosis) and CD133 (CSC content) were determined by 
flow cytometry. Self-renewal was assessed by sphere formation assay and 
response to gemcitabine treatment was used as a readout for chemoresistance.
RESULTS 
Analysis of our previously published RNAseq dataset E-MTAB-3808 revealed up-
regulation of genes involved in the KEGG (Kyoto Encyclopedia of Genes and 
Genomes) Pathway Glutathione Metabolism in CSC-enriched cultures compared 
to their differentiated counterparts. Consistently, in pancreatic cancer patient 
samples the expression of most of these up-regulated genes positively correlated 
with a stemness signature defined by NANOG, KLF4, SOX2 and OCT4 expression 
(P < 10-5). Moreover, 3 of the upregulated genes (MGST1, GPX8, GCCT) were 
associated with reduced disease-free survival in patients [Hazard ratio (HR) 2.2-
2.5; P = 0.03-0.0054], suggesting a critical role for this pathway in pancreatic 
cancer progression. CSC-enriched sphere cultures also showed increased 
expression of different glutathione metabolism-related genes, as well as enhanced 
glutathione content in its reduced form (GSH). Glutathione depletion with BSO 
induced cell cycle arrest and apoptosis in spheres, and diminished the expression 
of stemness genes. Moreover, treatment with either BSO or the glutathione 
recycling inhibitor 6-AN inhibited self-renewal and the expression of the CSC 
marker CD133. GSH content in spheres positively correlated with intrinsic 
resistance to gemcitabine treatment in different PDXs r = 0.96, P = 5.8 × 1011). 
Additionally, CD133+ cells accumulated GSH in response to gemcitabine, which 
was abrogated by BSO treatment (P < 0.05). Combined treatment with BSO and 
gemcitabine-induced apoptosis in CD133+ cells to levels comparable to CD133- 
cells and significantly diminished self-renewal (P < 0.05), suggesting that 
chemoresistance of CSCs is partially dependent on GSH metabolism.
CONCLUSION 
Our data suggest that pancreatic CSCs depend on glutathione metabolism. 
Pharmacological targeting of this pathway showed that high GSH content is 
essential to maintain CSC functionality in terms of self-renewal and 
chemoresistance.
Key Words: Pancreatic cancer; Cancer stem cells; Glutathione; Self-renewal; 
Chemoresistance; Redox
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Core Tip: Several glutathione metabolism genes are upregulated in pancreatic cancer 
stem cells (CSCs), and their expression correlates with a stemness signature and 
predicts survival in clinical samples. Increased glutathione concentration in CSCs 
promotes viability, cell cycle progression and pluripotency gene expression. Inhibition 
of glutathione synthesis or recycling impairs CSC functionalities such as self-renewal 
and chemoresistance. Our data demonstrate a targetable metabolic vulnerability of this 
aggressive subpopulation of cancer cells.
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INTRODUCTION
Pancreatic cancer has the worst outcome of any cancer in the world, and is currently 
the 3rd most frequent cause of cancer-related deaths[1]. At the same time, the incidence 
of pancreatic cancer keeps increasing, with approximately 448000 new cases in 2019. 
This number is predicted to further increase in the coming years and, due to its 
extreme lethality and lack of effective treatments available[2], pancreatic cancer may 
even become the 2nd most frequent cause of cancer-related deaths by 2030[3].
One possible explanation for the poor outcome associated with pancreatic cancer is 
that, previously, only little attention had been paid to the efficient elimination of 
cancer stem cells (CSCs). Pancreatic cancer contains stem cell-like cells, which are the 
sole drivers of tumorigenesis, much like normal stem cells fuel proliferation and 
differentiation in normal tissue, and therefore have been termed CSCs[4-8]. While CSCs 
represent only a small fraction of all the cancer cells, they are extremely tumorigenic 
down to a single cell, and exclusively metastatic[4,6]. Current treatment strategies for 
pancreatic cancer spare CSCs due to their inherent chemoresistance[8-10] and therefore 
likely represent the key cellular source driving disease relapse. To develop more 
effective treatment strategies for pancreatic cancer, we need to obtain a thorough 
understanding of the regulatory machinery of CSCs, including their cellular 
metabolism.
Increasing evidence suggests that, similar to normal stem cells, cellular metabolism 
is highly regulated in CSCs and governs essential aspects of their functionality. 
Indeed, a reduced intracellular redox state with low reactive oxygen species (ROS) 
levels allows for self-renewal, while ROS accumulation induces differentiation[11]. Since 
relatively high amounts of ROS are formed as by-products of mitochondrial oxidative 
phosphorylation, glycolysis was traditionally considered the preferred metabolic 
pathway for both stem cells and CSCs[12]. However, CSCs across a wide range of 
cancers maintain low ROS levels[13-15], even if they favor mitochondrial metabolism as 
their dominant energy-producing pathway[16]. In particular, we have shown that 
pancreatic CSCs are dependent on mitochondrial oxidative phosphorylation for full 
stemness and tumorigenicity, in a process controlled by the balanced expression of c-
MYC and the mitochondrial biogenesis factor PGC-1α[7]. We observed that pancreatic 
CSCs bear low levels of mitochondrial ROS and they are especially sensitive to the 
mitochondrial ROS inducer menadione, making the redox state of this organelle a 
relevant target for CSC elimination.
Glutathione (L-γ-glutamyl-L-cysteinyl-glycine; GSH) is the most abundant non-
protein antioxidant in eukaryotic cells. Although it is synthesized in the cytosol, 
glutathione levels are particularly high in mitochondria, where it maintains redox 
balance through ROS detoxification and protects phospholipids in the mitochondrial 
membrane[17]. Interestingly, glutathione levels are strongly increased in murine 
embryonic stem cells and mesenchymal stem cells, supporting defense against diverse 
insults and maintenance of stemness[18]. Similarly, glutathione content and specific 
GSH-related enzymes are up-regulated in CSCs from breast[13], liver[19] and gastric 
cancer[14]. Additionally, different components of the glutathione metabolism pathway 
have been shown to promote tumor initiation[20], metastasis[21,22] and chemoresist-
ance[23]; features frequently associated with CSCs.
However, little is known about the role of this pathway in pancreatic CSCs. Here we 
now show that pancreatic CSCs display increased GSH content and expression of 
diverse genes involved in the glutathione metabolism pathway, which correlated with 
stemness and disease-free survival in pancreatic cancer patients. Depletion of GSH 
levels in sphere cultures with pharmacological inhibitors of glutathione synthesis or 
recycling induced cell cycle arrest and apoptosis. This translated into diminished self-
renewal capacity and reduced expression of the CSC surface marker CD133. 
Importantly, GSH depletion sensitized CSCs to gemcitabine, suggesting an important 
role for glutathione in chemoresistance in pancreatic cancer.
MATERIALS AND METHODS
Primary human pancreatic cancer cells
Human pancreatic cancer Patient-Derived Xenografts [PDXs, either pancreatic ductal 
adenocarcinoma (PDAC) or pancreatic cancer of hepatobiliary origin] were obtained 
through the Biobank of the Spanish National Cancer Research Centre (CNIO), Madrid, 
Spain (reference 1204090835CHMH). For primary cultures, PDX tissue fragments 
previously expanded in nude mice (passages 1-13) were minced, enzymatically 
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digested with collagenase (Stem Cell Technologies, Vancouver, Canada) for 90 min at 
37°C[24], and after centrifugation for 5 min at 1200 rpm the pellets were resuspended 
and cultured in RPMI, 10% fetal  bovine serum (FBS),  and 50 U/mL 
penicillin/streptomycin. For the experiments, cells were cultured in DMEM:F12 
supplemented with B-27, L-Glutamine (all from Gibco, Life Technologies, Carlsbad, 
CA, USA), 50 U/mL penicillin–streptomycin (Sigma-Aldrich, St. Louis, MO, USA) and 
β-FGF (PeproTech, Rocky Hill, NJ, USA).
CSC-enriching culture
Pancreatic cancer spheres were generated and expanded in supplemented DMEM-F12. 
A total of 104 cells/mL was seeded in ultra-low attachment plates (Corning, Corning, 
NY, USA) as described previously[25].
Sphere formation assay
Cells were seeded in triplicate in ultra-low attachment 24-well plates (Corning) at 104 
cells/well in supplemented DMEM-F12 with or without the corresponding treatments, 
which were refreshed every other day.  After 7 d, spheres were counted using a 
microscope at 20× magnification.
RNA preparation and real-time polymerase chain reaction
Total RNAs from human primary pancreatic cancer cells and spheres were extracted 
with the TRIzol kit (Life Technologies) according to the manufacturer’s instructions. 
One microgram of total RNA was used for cDNA synthesis with SuperScript II reverse 
transcriptase (Life Technologies) and random hexamers. Quantitative real-time 
polymerase chain reaction (PCR) was performed using SYBR Green PCR master mix 
(Qiagen, Hilden, Germany), according to the manufacturer’s instructions. The list of 
utilized primers is detailed in Table 1.
GSH content
The glutathione-sensitive fluorescent probe monochlorobimane (mCLB, Sigma-
Aldrich) was used to analyze the reduced intracellular glutathione content. Cells were 
trypsinized on the day of the experiment, washed, protected from light and incubated 
for 1 h at 37°C with 2 mmol/L mCLB diluted in phosphate buffered saline (PBS). Cells 
were then washed and resuspended in PBS and fluorescence (excitation: 380 nm, 
emission: 461 nm) was measured on a FLUOstar OPTIMA Microplate Reader. Values 
were corrected for cell content by measuring the protein concentration of the sample 
with the Bradford assay. Alternatively, cells were incubated with DAPI and analyzed 
by flow cytometry using a FACS Canto II (BD, Franklin Lakes, NJ, USA) and data were 
analyzed with FlowJo 9.2 software (Ashland, OR, USA) or Cytobank (Beckman 
Coulter, CA, USA).
CSC content by flow cytometry
To identify pancreatic CSCs, the anti-CD133/1 (APC or PE, Miltenyi Biotec, Bergisch 
Gladbach, Germany) or corresponding control Immunoglobulin G (IgG) 1 antibody 
were used. Briefly, cells were stained for 30 min on ice with gentle rocking. DAPI was 
used for exclusion of dead cells (eBiosciences, San Diego, CA, USA). All samples were 
analyzed by flow cytometry using a FACS Canto II (BD) and data were analyzed with 
FlowJo 9.2 software or Cytobank.
Apoptosis assay by flow cytometry
Five-day old spheres or adherent cultures were treated for 48 h in the presence of 100 
mmol/L buthionine-sulfoximine (BSO) or BSO and gemcitabine (1 μmol/L). Attached 
and floating cells were collected, resuspended and stained with Annexin V (550474) 
diluted in Annexin V binding buffer (556454, all from eBiosciences) for 20 min at room 
temperature, following the manufacturer’s instructions. Cells were then incubated 
with DAPI for an additional 5 min.
Cell-cycle analysis by flow cytometry
Spheres were trypsinized, washed in PBS, centrifuged, and pellets were fixed in 200 µL 
of 70% ethanol and stored at -20°C until use. The cells were centrifuged and pellets 
resuspended in 200 µL of PBS, 10 µg/mL of RNAse A was added and the cells were 
incubated for 1 h at 37°C. Subsequently, the cells were resuspended in propidium 
iodide solution (0.1% sodium citrate, 0.1% TritonX-100, and 50 µg/mL propidium 
iodide).
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RNAseq data of CSC-enriched conditions
Expression of the genes contained in the KEGG (Kyoto Encyclopedia of Genes and 
Genomes) Pathway Glutathione Metabolism was investigated in our published 
RNAseq dataset E-MTAB-3808 (Array Express), which compares primary PDX cells 
cultured either by adherence or as spheres[7]. All original bioinformatic analyses on this 
dataset E-MTAB-3808 were performed at the Bioinformatics Unit and Structural 
Biology and Biocomputing Programme, Spanish National Cancer Research Centre 
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(CNIO), Madrid 28029, Spain. Differential expression of genes across the different 
conditions was calculated with Cuffdiff[26].
Human data analysis
Expression data from pancreatic cancer and normal tissue from the TCGA and the 
GTEx projects were analyzed using the webserver GEPIA2[27]. Pearson correlation 
coefficient was calculated for correlation analysis of glutathione-related genes with a 
stemness signature defined by the combined expression of the pluripotency-related 
genes NANOG, KLF4, SOX2 and OCT4. For disease-free survival analysis, the Hazard 
ratio (HR) was calculated using the Cox Proportional Hazards model for pancreatic 
cancer patients from upper and lower quartiles of expression of the indicated genes.
Statistical analyses 
Results for continuous variables are presented as mean ± SE unless stated otherwise. 
Treatment groups were compared with the independent samples t-test. Pair-wise 
multiple comparisons were performed with the one-way ANOVA (two-sided) with 
Bonferroni adjustment. Correlation analysis was performed by calculating the Pearson 
correlation coefficient. P values < 0.05 were considered statistically significant. All 
analyses were performed using Prism GraphPad (version 5.04).
RESULTS
Connection of glutathione metabolism with stemness in human pancreatic cancer 
samples 
In order to determine a possible connection between glutathione metabolism and 
stemness in pancreatic cancer, we first analyzed our previously published RNAseq 
dataset E-MTAB-3808 comparing 5 different PDAC PDX models cultured in 
differentiating (adherent) or CSC-enriching (spheres) conditions (Figure 1A)[7]. We 
focused on genes related to the KEGG Pathway Glutathione Metabolism, which we 
categorized into four different classes: Gamma-glutamyltransferases (GGTs), 
glutathione-s-transferases (GSTs), glutathione peroxidases (GPXs), and genes involved 
in glutathione synthesis and recycling. As summarized in Table 2, CSC-enriched 
cultures generally up-regulated genes from the four classes, although the specific 
genes varied among the different PDXs.
We have previously demonstrated that pancreatic CSCs show increased expression 
of several pluripotency-related genes such as NANOG, KLF4, SOX2 and OCT4, which 
we have routinely used as a stemness signature[5-7]. In order to further support a 
connection between glutathione metabolism and stemness, we used the webserver 
GEPIA2 to analyze our target genes in human expression data from normal pancreas 
and PDAC tissues included in the TCGA and GTEx projects. Thus, we performed gene 
expression correlation studies between the different glutathione-related genes up-
regulated in spheres and our defined stemness signature in normal vs PDAC samples. 
Interestingly, expression of 17 of the 25 genes up-regulated in CSCs positively 
correlated with the stemness signature in human samples, with P-values below 10-5 
(Figure 1B). Since disease recurrence can be mainly attributed to CSCs due to their 
ability to regenerate tumors following treatment, we next investigated whether the 
expression of any of the 17 genes correlated with disease-free survival in patients 
(Figure 1C). We found that high expression of MGST1, GPX8 and GGCT predicted 
between 2.2-2.5 times increased risk of recurrence in PDAC patients (P = 0.0054, 0.03 
and 0.0054, respectively). Together, our results suggest a functional link between 
glutathione metabolism, stemness and the aggressiveness of pancreatic cancer.
Glutathione metabolism is enhanced in primary sphere cultures of pancreatic 
cancer PDXs
Next, we aimed to further validate the above RNAseq results. Therefore, we analyzed 
the expression of 2-4 genes from each subgroup by real-time PCR. We included two 
additional PDX models [one PDAC (PDX163) and one pancreatic tumor of 
hepatobiliary origin (PDX247)] resulting in a total of seven PDX models for this 
validation. As shown in Figure 2, we detected enhanced expression of glutathione 
metabolism genes in CSC-enriching conditions for all seven PDX models, ranging 
between 2.5 to 600-fold.
For further functional validation, we used the thiol-sensitive probe 
monochlorobimane to assess the content of intracellular glutathione content in its 
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Table 2 RNAseq reveals that glutathione metabolism genes are up-regulated in cancer stem cell-enriched cultures from pancreatic 
cancer patient-derived xenografts
PDX GGTs GSTs GPXs Synthesis and recycling
PDX185 GGT1, GGT2, GGT3P, GGT6, GGT7 GSTA1, GSTA2, GSTT1, MGST2, MGST3 GPX2, GPX3 GCLC, GSR, PGD, IDH1
PDX215 GGT1, GGT2, GGT7, GGT8P GSTA1, GSTA4, GSTM2, GSTM4, MGST2 OPLAH, IDH1
PDX253 GGT1, GGT2, GGT3P, GGT6 GSTA1, GSTA2, GSTA4, MGST1, MGST2, 
MGST3
GPX2, GPX8 GSR, IDH1
PDX354 GSTA1, GSTA2, MGST1, GSTM2 GPX3, GPX8 GCLC, GGCT, IDH1
PDX265 GSTA4, GSTM1, GSTM2, GSTM4 GPX2 GGCT, PGD, IDH1, IDH2
PDX: Patient-derived xenograft; GGTs: Gamma-glutamyltransferases; GSTs: Glutathione-s-transferases; GPXs: Glutathione peroxidases.
reduced form (GSH). First, we measured the GSH content in primary cells cultured in 
adherent or sphere conditions using the same panel of seven PDX models. 
Interestingly, except for PDX247 (of hepatobiliary origin) GSH content was 2 to 8 times 
higher in CSC-enriching conditions (Figure 3A; P values < 0.05-0.01), reinforcing the 
results obtained by gene expression analysis. Next, we validated the increased GSH 
levels observed by analyzing CD133– and CD133+ subpopulations by flow cytometry. 
As shown in Figure 3B and 3C, CD133+ CSCs accumulated more intracellular GSH 
(1.94-fold, P = 0.04). In summary, our results indicate that expression of glutathione 
metabolism genes and GSH content are upregulated in CSC-enriched conditions.
Depletion of GSH content impairs CSC functionality
In order to evaluate the significance of the increased GSH content for CSCs, we 
performed a series of GSH depletion assays using two distinct pharmacological 
approaches. We first tested the inhibitor of GSH synthesis BSO, which irreversibly 
blocks the enzyme gamma-glutamylcysteine synthetase (γ-GCS). Incubation of CSC-
enriched spheres with increasing doses of BSO for 48 h resulted in a dose-dependent 
decline in GSH content, and with doses > 50 µmol/L depleted the GSH content below 
50% (Figure 4A; P values ranging between 0.0023 and 0.00032). Treatment of CSC-
enriched spheres with BSO at 100 µmol/L for 48 h resulted in the accumulation of cells 
in G1 phase, indicative of cell cycle arrest (Figure 4B). In addition, we observed an 
increase in the percentage of cells in both early and late apoptosis after BSO treatment, 
suggesting that full GSH content is necessary for proliferation and survival of CSCs 
(Figure 4C).
Considering these results, we next focused on alternative features directly linked to 
CSCs. First, BSO treatment decreased the expression of the aforementioned stemness 
signature defined by NANOG, KLF4, SOX2 and OCT4 (Figure 5A). Next, we measured 
the effect of BSO on CSC self-renewal. Since we had observed an up-regulation of 
genes involved in GSH recycling (Table 2), we also tested the GSH recycling inhibitor 
6-aminonicotinamide (6-AN), which blocks the oxidative branch of the pentose 
phosphate pathway that is necessary for reduction of oxidized GSSG into GSH. 
Incubation with either BSO or 6-AN consistently reduced the number of spheres 
formed by day 7, indicative of diminished self-renewal capacity (Figure 5B). 
Consistently, the percentage of CD133+ cells assessed by flow cytometry was also 
reduced following treatment with either inhibitor (Figure 5C).  Together these results 
indicate that depletion of GSH content directly impacts CSC viability and self-renewal.
Depletion of GSH content in CSC-enriched cultures enhances response to 
gemcitabine
Apart from the ability to self-renew, another key feature of CSCs is chemoresistance. 
Notably, several glutathione-related enzymes such as GSTs are directly implicated in 
detoxification of xenobiotics, suggesting another potential link between glutathione 
metabolism and CSC features[28]. Indeed, we found that the absolute GSH 
concentration in spheres, but not adherent cultures, positively correlated with the 
percentage of surviving cells after gemcitabine treatment (Figure 6A; Pearson’s r = 
0.96, P = 5.89 × 10-11). Gemcitabine treatment induced GSH accumulation exclusively in 
CD133+ cells (Figure 6B), which was abrogated by co-treatment with BSO. This 
translated in sensitization of CD133+ cells to treatment with gemcitabine, 
approximating levels of apoptosis observed in differentiated CD133– cells (Figure 6C), 
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Figure 1 Expression of glutathione metabolism genes positively correlates with a stemness signature in human pancreatic cancer 
samples and predicts poor outcome. A: Enrichment in CD133+ cells in sphere cultures vs adherent cultures, as determined by flow cytometry. Representative 
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flow cytometry histograms of the indicated patient-derived xenograft models; B: Correlation of genes that were up-regulated in cancer stem cell-enriched cultures with 
a stemness signature defined by combined expression of the pluripotency-related genes NANOG, KLF4, SOX2 and OCT4. Pearson´s r and corresponding P values 
for individual correlations are shown; C: Disease-free survival in pancreatic cancer patients from upper and lower quartiles of expression of the indicated genes. 
Hazard ratio was calculated using the Cox Proportional Hazards model. Dotted lines represent the 95% confidence interval. Data in A and B were calculated using 
GEPIA2 (http://gepia2.cancer-pku.cn), using public data compiled in TCGA and GTEx. Sph: Sphere culture; Adh: adherent culture; HR: Hazard ratio.
Figure 2 Glutathione metabolism-related genes are up-regulated in cancer stem cell-enriched conditions. Primary cells from different patient-
derived xenograft models as indicated in the figure were cultured in adherent or low-attachment cancer stem cell-enriching conditions. On day 7 the expression of 
several glutathione (GSH)-related genes was evaluated by real-time polymerase chain reaction (PCR). A: Glutathione-S-Transferases A1, A2, A4, M1; B: Gamma-
glutamyltransferases 1 and 2; C: Glutathione Peroxidases 1 and 2; D: Isocitrate Dehydrogenases 1 and 2. Data were normalized to HPRT and are shown as mean ± 
SE fold change expression levels of sphere vs adherent cultures in logarithmic scale. aP < 0.05; bP < 0.01; cP < 0.001. PDX: Patient-derived xenograft; GGT: Gamma-
glutamyltransferase; GST: Glutathione-s-transferase; GPX: Glutathione peroxidase.
and diminished sphere formation as compared to single treatments (Figure 6D; P < 
0.05). These results demonstrate that chemoresistance in CSCs is, at least in part, 
dependent on GSH synthesis.
In summary, our results suggest that glutathione metabolism plays an essential role 
in PDAC aggressiveness, supporting CSC survival, self-renewal and chemoresistance.
DISCUSSION
Any living cell produces ROS, either as a by-product of mitochondrial respiration or in 
a controlled manner by different oxidases to modulate cell signaling. Specifically, 
intracellular ROS levels regulate the complex balance between symmetric and 
asymmetric division in stem cells, thus controlling differentiation and self-renewal[29]. 
In these cells, avoiding ROS accumulation is particularly important, since it prevents 
the accumulation of hereditary mutations and premature senescence[30]. For these 
reasons, quiescent stem cells reside in a low oxygen niche favoring glycolysis over 
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Figure 3 Reduced glutathione content is increased in cancer stem cell-enriching conditions. Reduced glutathione (GSH) content was measured 
using the fluorescent thiol-reactive probe monochlorobimane (mClB). A: GSH content in cellular lysates was assessed by fluorimetry.  Primary cells from different 
patient-derived xenograft (PDX) models as indicated in the figure were cultured in adherent or low-attachment cancer stem cell-enriching conditions for 7 d. Data 
were normalized for protein content; B: GSH content in CD133 positive and negative subpopulations as determined by flow cytometry. Representative flow cytometry 
histograms of the indicated PDX models are shown, with the following mean fluorescence intensities (MFI) for CD133– and CD133+ populations, respectively: 
PDX215 (2787 vs 4880), PDX286 (2748 vs 4364), PDX354 (4138 vs 6988); C: Pooled MFI data from PDX215, 286 and 354. Data in A and C are shown as mean ± 
SE fold change for sphere vs adherent cultures (A) or CD133+ vs CD133–. aP < 0.05; bP < 0.01. GSH: Glutathione content in its reduced form; PDX: Patient-derived 
xenograft; Sph: Sphere culture; Adh: adherent culture; MFI: Mean fluorescence intensities.
mitochondrial respiration and express high levels of antioxidant systems[18,31].
Similar to normal stem cells, publications on different cancer types indicate that 
CSCs have lower ROS levels than their differentiated counterparts to support self-
renewal and tumorigenicity[13,14,19]. However, the mechanisms by which they keep a 
reduced redox state may differ, since many CSCs depend on mitochondrial oxidative 
metabolism[12,16]. In fact, while glycolysis maintains reduced ROS levels in gemcitabine-
resistant pancreatic PaTU8988 cells[32], primary human pancreatic CD133+ CSCs have 
low mitochondrial ROS concomitant with full oxidative metabolic (OXPHOS) 
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Figure 4 Inhibition of glutathione synthesis blocks cell cycle progression and induces apoptosis in cancer stem cell-enriched cultures. 
Cells from the indicated patient-derived xenograft models were grown in cancer stem cell-enriching conditions as spheres for 5 d and then treated for 48 h with 100 
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µmol/L buthionine-sulfoximine (BSO), unless indicated otherwise. A: Dose-dependent inhibition of glutathione (GSH) content by BSO measured by fluorimetry after 
staining with monochlorobimane (mClB); B: Percentage of cells in the different phases of the cell cycle as assessed by flow cytometry; C: Representative FACS plots 
of an Annexin-V/DAPI staining to detect apoptosis under the indicated conditions. GSH: Glutathione content in its reduced form; BSO: Buthionine-sulfoximine; PDX: 
Patient-derived xenograft.
activity[7]. These findings suggest that, rather than controlling ROS release from the 
primary production site, CSCs favor ROS detoxification as a common feature. Indeed, 
CD44+CD24+ Panc-1 cells survive radiation by blocking ROS accumulation, which also 
points to increased ROS scavenging in CSCs[33].
GSH is a key antioxidant defense in mammalian cells, maintaining intracellular 
redox homeostasis. Coupled to different enzymes such as GPXs or GSTs, GSH not only 
reacts with ROS and electrophiles, but also prevents oxidation of thiol groups in 
proteins, acts as a cysteine reserve pool, and detoxifies xenobiotics[28]. Interestingly, 
most of the representative works describing low ROS content in CSCs also reported 
high levels of GSH and/or GSH-related enzymes. For example, GCLM and GSS were 
upregulated in liver CD13+N-cadherin- CSCs[19], and GSH content and GPXs expression 
were increased in gastric CD44+ cells[14]. In addition, breast CSCs defined either as 
CD24–/Low CD44+Lin–  or ALDH+ showed elevated GSH concentration and 
glutathione synthesis enzymes[13,34], which, in the case of ALDH+ cells, was further 
enhanced with upregulation of GPXs and GSTs[34,35].
To date, the few published reports connecting glutathione metabolism and 
stemness-related features in pancreatic cancer have focused on GPXs, with different 
isoforms playing contradictory roles. On the one hand, GPX1 was described to play a 
tumor suppressor role counteracting features attributed to CSCs in MiaPaca-2 cells. 
GPX1 overexpression inhibited clonogenicity and tumor growth in vivo[36], while GPX-1 
silencing induced EMT (epithelial-to-mesenchymal transition) and chemoresistance[37]. 
On the other hand, Panc-1 spheroids up-regulate GPX1 and GPX4 in hypoxic 
conditions, but only GPX4 seems to be important for self-renewal and invasion under 
both normoxia and hypoxia[38].
Here, we show that CSC-enriched cultures established from 7 human PDX models 
not only up-regulate several GPX genes, but also numerous genes related to GSH 
synthesis and recycling, as well as GSTs (Table 2 and Figure 2). However, although 
there is a global upregulation of the pathway, our results suggest that expression 
patterns of the specific isoform(s) of GPXs and GSTs expressed vary considerably 
across patients (Table 2). This apparent heterogeneity argues against the universality 
of the previously mentioned studies on GPX isoforms, which were based on just one or 
two established cell lines[36-38]. Interestingly, our analysis of human normal or PDAC 
samples indicate a strong correlation of GSH-related genes with stemness and poor 
outcome (Figure 1). In addition, and in line with the gene expression data, intracellular 
GSH levels were also increased in spheres and CD133+ cells, respectively, as compared 
to differentiated cells (Figure 2). Together, these results support the notion that 
pancreatic CSCs resemble CSCs from other cancer types in terms of glutathione 
metabolism, and corroborate the evidence for the crucial role of this pathway in cancer 
stemness.
Oxidative CSCs need to counteract ROS produced in cellular respiration. Notably, 
enhanced GSH metabolism is often linked to increased mitochondrial function, 
conferring protection from ROS produced during respiration and by detoxifying lipid 
hydroperoxides and electrophiles[28]. In fact, glutathione peroxidases such as GPX4 or 
transferases such as GSTP have been shown to maintain OXPHOS activity and 
preserve mitochondrial function[39,40]. Importantly, OXPHOS metabolism is linked to 
glutathione metabolism and antioxidative defense via a process controlled by NRF2, 
thereby promoting breast CSCs maintenance and self-renewal[34]. In this context, we 
have previously shown that PGC-1α promotes mitochondrial respiration and is 
required for full stemness, connecting both processes in pancreatic CSCs[7]. 
Interestingly, one of the main physiological functions of PGC-1α is to balance 
mitochondrial ROS production and scavenging by coordinating mitochondrial 
biogenesis and antioxidative response. Indeed, PGC-1α has been shown to control the 
expression of several antioxidants and glutathione-related enzymes such as GPXs and 
GSTs, likely via NRF2 activation[41,42]. Moreover, it modulates GSH levels by regulating 
its synthesis through direct gamma-glutamylcysteine ligase and glutathione synthase 
transcriptional control[41,43]. Therefore, glutathione metabolism could support stemness 
downstream of PGC-1α in pancreatic CSCs by detoxifying mitochondrial ROS.
Our results suggest that pancreatic CSCs are particularly sensitive to glutathione 
depletion. We have shown that inhibition of GSH synthesis induces cell cycle arrest 
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Figure 5 Inhibition of glutathione synthesis and recycling decreases self-renewal and CD133 expression. Cells from the indicated patient-
derived xenografts (PDXs) were treated with 100 µmol/L buthionine-sulfoximine or 1 µmol/L 6-Aminonicotinamide as indicated. A: Expression of stemness gene 
expression following 72 h of treatment; B: Sphere formation ability after 7 d of treatment, replenished every other day. Data are shown as fold change vs untreated 
conditions (Cont) for each PDX model, mean ± SE; C: Representative flow cytometry plots for CD133 expression after 48 h of treatment. aP < 0.05; bP < 0.01; cP < 
0.001. BSO: Buthionine-sulfoximine; PDX: Patient-derived xenograft; 6-AN: 6-Aminonicotinamide.
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and apoptosis of pancreatic CSCs (Figure 4), resulting in reduced expression of 
stemness genes, self-renewal capacity and, consequently, CD133+ content (Figure 5). In 
contrast, breast and colorectal CSCs seem to be resistant to BSO as a single treatment, 
and they up-regulate thioredoxins as a compensatory mechanism to counteract ROS 
and maintain self-renewal under BSO treatment[34,44]. Interestingly, inhibition of self-
renewal was achieved not only with the glutathione synthesis inhibitor BSO, but also 
by pharmacological inhibition of GSH recycling using 6-AN. These results functionally 
validate our RNAseq data, in which we observed that pancreatic CSCs upregulated 
genes related to both synthesis (GCLC) and recycling processes (GSR, PGD), and 
suggest that GSH metabolism is highly dynamic in pancreatic CSCs. Of note, the 
specific balance of synthesis vs recycling processes determining the actual GSH content 
may vary between patients. For example, PDX215 cells were partially resistant to BSO, 
while they responded to 6AN similarly to the other PDXs tested (Figure 5).
Depletion of intracellular GSH with BSO has been shown to sensitize breast CSCs to 
radiotherapy, inducing oxidative DNA damage that leads to apoptosis[13,45]. However, 
glutathione synthesis inhibition has been mainly tested in combination with 
conventional chemotherapy: Treatment with BSO enhanced toxicity of melphalan[46], 
paclitaxel[47], cisplatin and gemcitabine[48] in different in vitro models, but showed no 
effect for 5-fluorouracil[46]. Our results further underscore the role of glutathione in 
chemoresistance, by regulating CSCs survival and functionality. First, we show that 
GSH content in CSC-enriched cultures, but not in adherent cultures, positively 
correlates with global survival under gemcitabine treatment (Figure 6A). Moreover, 
we found that CD133+ cells, but not CD133–, accumulate more intracellular GSH in 
response to gemcitabine (Figure 6B). Counteracting this defense response by BSO 
treatment induced apoptosis in both subpopulations to a similar degree (Figure 6C).
Other combination therapies involving glutathione synthesis inhibition have been 
tested in pancreatic cancer with reasonable success. For instance, inhibition of the 
PI3K/AKT pathway in combination with BSO blocked mRNA translation and 
impaired tumor growth in vivo, mimicking NRF2 loss in pancreatic cancer[49]. Although 
BSO is the most utilized treatment to achieve GSH depletion, other strategies such as 
inhibition of cysteine/glutamate transport showed a synergistic effect in combination 
with gemcitabine for inhibiting proliferation of pancreatic cancer cell lines[50].
CONCLUSION
In summary, we find that glutathione metabolism plays an essential role in pancreatic 
cancer aggressiveness, supporting CSC survival, self-renewal and chemoresistance. 
Our results point to a novel metabolic vulnerability of pancreatic CSCs that should be 
exploited for the design of new therapeutic strategies aimed at the elimination of this 
highly aggressive subpopulation of cancer cells.
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Figure 6 Depletion of glutathione (GSH) content in cancer stem cells enhances response to Gemcitabine. A: Correlation of the absolute 
glutathione (GSH) content per milligram of protein in lysates from adherent (left panel) or sphere (right panel) cultures vs the percentage of surviving cells following 
gemcitabine treatment (300 nM, 48 h). Values for Pearson´s r and corresponding P values are shown; B-D: Patient-derived xenograft 354 cells were treated with 100 
µmol/L buthionine-sulfoximine (BSO) alone or in combination with 1 µmol/L Gemcitabine; B: mClB staining for GSH content in CD133– vs CD133+ cells after 48 h of 
treatment; C: Representative flow cytometry plots for Annexin V/DAPI staining for samples shown in B; D: Number of spheres following 7 d of treatment. Data in B 
and D are shown as mean fold change or mean percentage ± SE, with untreated conditions (Cont) set as 1.0 or 100%, respectively. aP < 0.001 vs Cont; bP < 0.001 
vs BSO; cP < 0.001 vs Gemcitabine. GSH: Glutathione content in its reduced form; PDX: Patient-derived xenograft; MFI: Mean fluorescence intensities; BSO: 
Buthionine-sulfoximine.
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ARTICLE HIGHLIGHTS
Research background
Redox metabolism modulates stem cell and cancer stem cell (CSC) functionality in 
different model systems, regardless of their dominant metabolic phenotype.  In fact, 
CSCs from several cancer types show increased glutathione content and associated 
enzymes.
Research motivation
Identification of metabolic vulnerabilities of highly aggressive CSCs can lead to the 
development of more effective treatment strategies for pancreatic cancer.
Research objectives
The present study aimed to determine the importance of glutathione metabolism for 
pancreatic CSCs as compared to their differentiated counterparts.
Research methods
Comparisons between CSCs and non-CSCs in primary pancreatic cancer cells of 
patient-derived xenografts were carried out by culturing in adherent or CSC-enriching 
sphere conditions and confirmed by CD133 staining by flow cytometry.  Gene 
expression analyses were performed by RNAseq or real-time PCR. Public TCGA and 
GTEx RNAseq data from pancreatic cancer vs normal tissue samples were analyzed 
using the webserver GEPIA2. Staining for measurement of glutathione 
(monochlorobimane), cell cycle (propidium iodide) or apoptosis (Annexin-V) were 
determined by fluorimetry or flow cytometry. Pharmacological glutathione depletion 
was achieved with inhibitors of glutathione synthesis (buthionine-sulfoximine) and 
recycling (6-Aminonicotinamide). Self-renewal was assessed by sphere formation 
assay and response to gemcitabine treatment was used as a readout for 
chemoresistance.
Research results
Several glutathione metabolism genes were upregulated in pancreatic CSCs, and their 
expression correlates with a stemness signature and predicts survival in clinical 
samples. Increased glutathione concentration in CSCs promotes viability, cell cycle 
progression and pluripotency gene expression. Inhibition of glutathione synthesis or 
recycling impairs CSC functionalities such as self-renewal and chemoresistance.
Research conclusions
Our data suggest that pancreatic CSCs depend on glutathione metabolism. 
Pharmacological targeting of this pathway showed that high GSH (glutathione in its 
reduced form) content is essential to maintain CSC functionality in terms of self-
renewal and chemoresistance.
Research perspectives
Our data demonstrate a targetable metabolic vulnerability of this aggressive 
subpopulation of cancer cells, which could be exploited for therapeutic purposes.
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